Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials

Нан the medicinal препараты в действии: обзор противораковых наномедицинских препаратов на рынке и в клинических исследованиях
Ruibing Wang, Wayne M. Mullett, Paul S. Billone
2013-01-01

cancer diagnostics and therapycancer nanomedicinenanoanalytical contrast reagentsnanodrug delivery systemsnanopharmaceuticals
Nanomedicine, defined as the application of nanotechnology in the medical field, has the potential to significantly change the course of diagnostics and treatment of life‐threatening diseases, such as cancer. In comparison with traditional cancer diagnostics and therapy, cancer nanomedicine provides sensitive cancer detection and/or enhances treatment efficacy with significantly minimized adverse effects associated with standard therapeutics. Cancer nanomedicine has been increasingly applied in areas including nanodrug delivery systems, nanopharmaceuticals, and nanoanalytical contrast reagents in laboratory and animal model research. In recent years, the successful introduction of several novel nanomedicine products into clinical trials and even onto the commercial market has shown successful outcomes of fundamental research into clinics. This paper is intended to examine several nanomedicines for cancer therapeutics and/or diagnostics‐related applications, to analyze the trend of nanomedicine development, future opportunities, and challenges of this fast‐growing area.
1
Cancer nanomedicine can improve cancer detection sensitivity and treatment efficacy while reducing adverse effects compared with traditional approaches.
2
Nanomedicine applications in cancer include nanodrug delivery systems, nanopharmaceuticals, and nanoanalytical contrast reagents.
3
Several cancer nanomedicine products have progressed from fundamental research into clinical trials and commercial markets, demonstrating translational potential.
4
The field is rapidly expanding, but its development involves future opportunities and challenges requiring continued evaluation.

Cancer nanomedicines, including nanodrug delivery systems, nanopharmaceuticals, and nanoanalytical contrast reagents, in clinical trials and on the commercial market

Their development trends, therapeutic and diagnostic applications, clinical outcomes, future opportunities, and challenges

Publication Details
Publication Date
2013-01-01
Journal
Publisher
ISSN
Cited by
236
Access Type
Author Information
Authors
Ruibing Wang
Wayne M. Mullett
Paul S. Billone
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%